Comparing Emmaus Life Sciences (NASDAQ:EMMA) & Livongo Health (NASDAQ:LVGO)

Emmaus Life Sciences (NASDAQ:EMMA) and Livongo Health (NASDAQ:LVGO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Valuation and Earnings

This table compares Emmaus Life Sciences and Livongo Health’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Emmaus Life Sciences $1.32 million 128.37 -$9.59 million ($11.16) -0.32
Livongo Health $68.43 million 34.01 -$33.38 million N/A N/A

Emmaus Life Sciences has higher earnings, but lower revenue than Livongo Health.


This table compares Emmaus Life Sciences and Livongo Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Emmaus Life Sciences -489.28% -511.05% -209.39%
Livongo Health N/A N/A N/A

Institutional & Insider Ownership

0.1% of Emmaus Life Sciences shares are owned by institutional investors. 36.9% of Emmaus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Emmaus Life Sciences and Livongo Health, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Emmaus Life Sciences 0 0 0 0 N/A
Livongo Health 0 1 9 0 2.90

Livongo Health has a consensus target price of $44.20, suggesting a potential upside of 79.38%. Given Livongo Health’s higher probable upside, analysts clearly believe Livongo Health is more favorable than Emmaus Life Sciences.


Livongo Health beats Emmaus Life Sciences on 6 of the 10 factors compared between the two stocks.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

Livongo Health Company Profile

Livongo Health, Inc. provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications. Its products include Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. The company was formerly known as EosHealth, Inc. and changed its name to Livongo Health, Inc. in 2014. Livongo Health, Inc. was incorporated in 2008 and is headquartered in Mountain View, California.

Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit